Filing Details
- Accession Number:
- 0001562180-19-003930
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-07-12 16:18:28
- Reporting Period:
- 2019-07-10
- Accepted Time:
- 2019-07-12 16:18:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 842023 | Bio-Techne Corp | TECH | Biological Products, (No Disgnostic Substances) (2836) | 411427402 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1534980 | R. Charles Kummeth | 614 Mckinley Pl Ne Minneapolis MN 55413 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-07-10 | 16,969 | $67.46 | 109,145 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-07-10 | 6,566 | $212.75 | 102,579 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-07-10 | 9,909 | $213.32 | 92,670 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-07-10 | 494 | $214.07 | 92,176 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to buy) | Disposition | 2019-07-10 | 16,969 | $0.00 | 16,969 | $67.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2020-04-01 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | $0.00 | 24,979 | 24,979 | Direct | ||
| Common Stock | Restricted Stock Units | $0.00 | 21,291 | 21,291 | Direct | ||
| Common Stock | Restricted Stock Units | $0.00 | 16,918 | 16,918 | Direct | ||
| Common Stock | Stock Option (Right to Buy) | $108.49 | 2022-08-07 | 79,517 | 79,517 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $106.59 | 2023-08-18 | 102,779 | 102,779 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $106.59 | 2023-08-18 | 154,169 | 154,169 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $86.25 | 2021-04-01 | 46,316 | 46,316 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $67.46 | 2020-04-01 | 65,000 | 65,000 | Direct | |
| Common Stock | Stock Options (Right to buy) | $177.32 | 2025-08-08 | 60,222 | 60,222 | Direct | |
| Common Stock | Stock Options (Right to buy) | $177.32 | 2025-08-08 | 90,334 | 90,334 | Direct | |
| Common Stock | Stock Options (Right to buy) | $125.05 | 2024-08-09 | 117,342 | 117,342 | Direct | |
| Common Stock | Stock Options (Right to buy) | $125.05 | 2024-08-09 | 78,228 | 78,228 | Direct | |
| Common Stock | Stock Options (Right to buy) | $94.35 | 2021-08-12 | 66,849 | 66,849 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 24,979 | 24,979 | Direct | |
| 21,291 | 21,291 | Direct | |
| 16,918 | 16,918 | Direct | |
| 2022-08-07 | 79,517 | 79,517 | Direct |
| 2023-08-18 | 102,779 | 102,779 | Direct |
| 2023-08-18 | 154,169 | 154,169 | Direct |
| 2021-04-01 | 46,316 | 46,316 | Direct |
| 2020-04-01 | 65,000 | 65,000 | Direct |
| 2025-08-08 | 60,222 | 60,222 | Direct |
| 2025-08-08 | 90,334 | 90,334 | Direct |
| 2024-08-09 | 117,342 | 117,342 | Direct |
| 2024-08-09 | 78,228 | 78,228 | Direct |
| 2021-08-12 | 66,849 | 66,849 | Direct |
Footnotes
- Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.285 to $212.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.00 to $213.95, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.03 to $214.21, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Fully exercisable
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Vests 19,879 shares on each of 8/7/16, 8/7/17 and 8/7/18 and 19,880 shares on 8/7/19.
- Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.
- Vests 15,056 shares each on 8/8/2019, 8/8/202 and 15,055 shares each on 8/8/2021, 8/8/2022
- Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
Billionaire Hedge Funds
